Mary Caffrey

An alternative dose of ipilimumab and nivolumab had less toxicity than a conventional dose, the results show.

Results are consistent with the authors' prior findings on the possible effects of circadian rhythm on outcomes after immunotherapy.

The Princess of Wales is likely referencing adjuvant chemotherapy, but there is a growing field of immunoprevention, which seeks to target precancerous lesions or block heritable cancers.

This is the second time the combination has failed to meet end points in a trial in non–small cell lung cancer (NSCLC).

The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care.

As pressure from the Biden administration on UnitedHealth Group increases, physicians' groups weigh in following the unprecedented hack on Change Healthcare.

Results come amid the FDA's review of chimeric antigen receptor (CAR) T-cell therapy.

In his State of the Union Address, the president called for expanding the number of drugs subject to Medicare price negotiations and extending a $2000 out-of-pocket cap beyond seniors.

Friday's keynote speaker, Katherine A. Meese, PhD, addressed the conference theme of workforce support at the Association of Cancer Care Centers 50th Annual Meeting and Cancer Center Business Summit.

The session at ACCC's 50th Annual Meeting & Cancer Center Business Summit featured discussions on patient navigation, addressing patients' sexual health, needs of LGBTQ+ patients, and more.

Coverage from the Association of Cancer Care Centers’ 50th Annual Meeting & Cancer Center Business Summit.

ONCare Alliance will be led by 2 of the leading women in community oncology, cochairs Barbara McAneny, MD, of the New Mexico Cancer Center, and Sibel Blau, MD, of Northwest Medical Specialties, PLLC, of Puyallup, Washington.

Quality Improvement (QI) projects require a series of distinct steps and timely data collection that will allow clinics to see if changes are yielding results, a consultant told attendees at a preconference workshop at ACCC.

The newly rebranded Association of Cancer Care Centers (ACCC) celebrates its 50th year at this week's business meeting.

An on-body delivery system approved last fall for paroxysmal nocturnal hemoglobinuria (PNH) has seen rapid uptake and is now being studied for use with isatuximab.

In this final part of our interview with James Robinson, PhD, MPH, he underscores the need for employer education about the health plans they offer, fostering managed competition among hospital systems to drive down costs, and innovation in financing drug development.

Approved in Europe, tabelecleucel may soon be considered by FDA to treat patients who develop Epstein-Barr virus following a transplant, which then triggers a type of deadly lymphoma that may not respond to traditional therapy. Tab-cel, an allogeneic T-cell therapy, comes 30 years after the discovery that T cells might offer hope, followed by decades of research on how to harness them without the side effects.

In part 3 of our interview with James Robinson, PhD, MPH, he discusses the need for reforms to commercial insurance that reflect the changes to Medicare under the Inflation Reduction Act, how the 340B drug pricing program has veered widely from its original goals, and ongoing cost sharing struggles among patients, insurers, hospitals, and drug companies.

In part 2 of our interview with Robinson, he addresses the potential for exacerbated health care disparities in the aftermath of hospital price markups and how insurance plan design often disadvantages the patients who most need expensive infusion therapies but cannot afford them.

Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy.

In the January issue of The New England Journal of Medicine, James Robinson, PhD, MPH, and his fellow investigators published their findings from an analysis of how insurer drug expenditures on infused drugs influenced price markups at hospitals.

Business and practice updates from our Strategic Alliance Partners.

Coverage from the session, "Bringing Health Equity to Clinical Trials at Every Step," at Patient-Centered Oncology Care 2023.

Coverage from the session, "Which Comes First? Bispecifics, CAR T-Cell Therapy, and Cost Consideration in Sequencing,” at Patient-Centered Oncology Care 2023.

Coverage of Tennessee Oncology's Johann Brandes, MD, on "Precision Medicine in NSCLC."

MD Anderson's Ryan Huey, MD, offers a survey of research on a holistic approach to addressing financial toxicity during Patient Centered Oncology Care 2023.

Coverage from the discussion, "Cancer Genomics: The Gateway to Access and Health Equity” on the first day of Patient-Centered Oncology Care 2023.

Kathryn E. Hudson, MD, of Texas Oncology was a featured speaker at Patient-Centered Oncology Care 2023.

FDA has approved budesonide oral suspension to treat patients 11 years of age and older with eosinophilic esophagitis (EoE). The oral therapy, to be sold as Eohilia, will be available by the end of February, according to sponsor Takeda.

A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.